{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:07:20Z","timestamp":1789564040417,"version":"build-2803163510"},"reference-count":105,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have significantly prolonged patient survival in cancer therapy; however, overactivated immune responses can lead to endocrine immune-related adverse events (irAEs), primarily manifesting as thyroid dysfunction, hypophysitis, adrenal insufficiency, and insulin-dependent diabetes mellitus. Some of these endocrine injuries are irreversible and lack early warning indicators. This narrative review summarizes current evidence regarding the mechanisms underlying ICI-induced endocrine toxicities, including immune checkpoint pathways, organ-specific autoimmune responses, host-related factors, predictive biomarkers, and emerging precision management strategies. It summarizes potential predictive biomarkers, including thyroid autoantibodies, cytokine profiles, and single-cell sequencing, and discusses emerging approaches, including imaging-based assessment, liquid biopsy, and multidimensional prediction models, while emphasizing their current limitations and the need for prospective validation. Finally, by integrating organ-specific mechanistic evidence, biomarker-based prediction, and risk-stratified monitoring, this review frames these advances within the concept of \u201cproactive endocrine protection,\u201d emphasizing the transition from passive toxicity management toward earlier identification and individualized surveillance.<\/jats:p>","DOI":"10.3389\/fendo.2026.1935980","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:33:00Z","timestamp":1789561980000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitor-related endocrinopathies: from immune crosstalk to predictive biomarkers and precision management"],"prefix":"10.3389","volume":"17","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Heilongjiang Academy of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Heilongjiang Academy of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyu","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Heilongjiang Academy of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Heilongjiang Academy of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanpeng","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Heilongjiang Academy of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Heilongjiang Academy of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Heilongjiang Academy of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","first-page":"3","article-title":"The treatment of Malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases","volume":"1991","author":"Coley","year":"1893","journal-title":"Clin Orthop Relat Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-021-00833-8","article-title":"A review of cancer immunotherapy toxicity: Immune checkpoint inhibitors","volume":"17","author":"Chhabra","year":"2021","journal-title":"J Med Toxicol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.04.002","article-title":"Adverse events following cancer immunotherapy: Obstacles and opportunities","volume":"40","author":"Pauken","year":"2019","journal-title":"Trends Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1701500","article-title":"Increased risk of hyperthyroidism induced by immune checkpoint inhibitors in patients with existing or prior Graves' disease: a nested prospective cohort study with propensity score matching","volume":"16","author":"Suzuki","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ19-0163","article-title":"Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society","volume":"66","author":"Arima","year":"2019","journal-title":"Endocr J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41574-024-01077-6","article-title":"Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors","volume":"21","author":"Iwama","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad231","article-title":"Risk of thyroid dysfunction in PD-1 blockade is stratified by the pattern of TgAb and TPOAb positivity at baseline","volume":"108","author":"Zhou","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac467","article-title":"Elevated TSH level, TgAb, and prior use of ramucirumab or TKIs as risk factors for thyroid dysfunction in PD-L1 blockade","volume":"107","author":"Kobayashi","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab829","article-title":"Increased risk of thyroid dysfunction by PD-1 and CTLA-4 blockade in patients without thyroid autoantibodies at baseline","volume":"107","author":"Iwama","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.836859","article-title":"Immune checkpoint inhibitor-induced hypophysitis and patterns of loss of pituitary function","volume":"12","author":"Jessel","year":"2022","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac689","article-title":"Approach to the patient with immune checkpoint inhibitor\u2013associated endocrine dysfunction","volume":"108","author":"Wright","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2533","article-title":"Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma","volume":"8","author":"Kassi","year":"2019","journal-title":"Cancer Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment","volume":"14","author":"Di Dalmazi","year":"2019","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1636452","article-title":"Initial symptoms and diagnostic delay in immune checkpoint inhibitor-related adrenal insufficiency: a systematic review and meta-ethnography of case reports","volume":"16","author":"Ohta","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01845-z","article-title":"Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: a retrospective analysis using the FAERS","volume":"45","author":"Lu","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"B23","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","article-title":"Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase report analysis","volume":"25","author":"Grouthier","year":"2020","journal-title":"Oncologist"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14362","article-title":"Immune checkpoint inhibitor-related type 1 diabetes incidence, risk, and survival association","volume":"16","author":"Kamitani","year":"2025","journal-title":"J Diabetes Investig"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2023.0072","article-title":"Immune-checkpoint inhibitors-induced type 1 diabetes mellitus: From its molecular mechanisms to clinical practice","volume":"47","author":"Cho","year":"2023","journal-title":"Diabetes Metab J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-00443-4","article-title":"Type 1 diabetes mellitus as a disease of the \u03b2-cell (do not blame the immune system?)","volume":"17","author":"Roep","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2337\/db22-0557","article-title":"Inflammatory cell infiltration into islets without PD-L1 expression is associated with the development of immune checkpoint inhibitor-related type 1 diabetes in genetically susceptible patients","volume":"72","author":"Kawata","year":"2023","journal-title":"Diabetes"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1530\/ec-22-0513","article-title":"Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer","volume":"12","author":"Percik","year":"2023","journal-title":"Endocr Connect"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011865","article-title":"Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors","volume":"13","author":"Zhu","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1530\/etj-24-0328","article-title":"Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors","volume":"14","author":"Yamauchi","year":"2025","journal-title":"Eur Thyroid J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/eje-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011271","article-title":"Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations","volume":"13","author":"Wu","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71818","article-title":"Endocrinologist-led management of endocrine immune-related adverse events: real-world evidence supporting the Japan Endocrine Society guidelines","volume":"15","author":"Nishihama","year":"2026","journal-title":"Cancer Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.r330","article-title":"Adrenal insufficiency: identification and management-summary of new NICE guidance","volume":"389","author":"Ftouh","year":"2025","journal-title":"Bmj"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1157805","article-title":"Endocrine side effects of immune checkpoint inhibitors","volume":"14","author":"Cardona","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139867","article-title":"PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy","volume":"10","author":"Sponaas","year":"2015","journal-title":"PloS One"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008591","article-title":"Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update","volume":"12","author":"Fletcher","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1447021","article-title":"Toxicity in the era of immune checkpoint inhibitor therapy","volume":"15","author":"Keam","year":"2024","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1584675","article-title":"Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms","volume":"16","author":"Mao","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg0675","article-title":"Clonally expanded, thyrotoxic effector CD8(+) T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis","volume":"15","author":"Lechner","year":"2023","journal-title":"Sci Transl Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01623-z","article-title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"101193","DOI":"10.1016\/j.diabet.2020.09.003","article-title":"Immune checkpoint inhibitors and diabetes: Mechanisms and predictors","volume":"47","author":"Youssef","year":"2021","journal-title":"Diabetes Metab"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1010279","article-title":"Thyroid-related adverse events induced by immune checkpoint inhibitors","volume":"13","author":"Chera","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1530\/ec-25-0697","article-title":"A systematic review of ipilimumab-induced hypophysitis","volume":"15","author":"Kim","year":"2026","journal-title":"Endocr Connect"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-024-00719-4","article-title":"Immune checkpoint inhibitor-related type 1 diabetes mellitus which develops long after treatment discontinuation: a case report and review of literature","volume":"15","author":"Obata","year":"2024","journal-title":"Diabetol Int"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030436","article-title":"Immunotherapy-related hypophysitis: A narrative review","volume":"17","author":"Di Stasi","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12103468","article-title":"Progress and challenges of immune checkpoint inhibitor-induced hypophysitis","volume":"12","author":"Chen","year":"2023","journal-title":"J Clin Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/med.0000000000000652","article-title":"Hypophysitis from immune checkpoint inhibitors: Challenges in diagnosis and management","volume":"28","author":"Kotwal","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2023.11.003","article-title":"Primary adrenal insufficiency induced by immune checkpoint inhibitors: Biological, clinical, and radiological aspects","volume":"50","author":"Martella","year":"2023","journal-title":"Semin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2018.03.008","article-title":"Autoimmune Addison's disease - An update on pathogenesis","volume":"79","author":"Hellesen","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1366335","article-title":"Challenges in autoimmune polyendocrine syndrome type 2 with the full triad induced by anti-programmed cell death 1: A case report and review of the literature","volume":"15","author":"Pan","year":"2024","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1683546","article-title":"Normal adrenocorticotropic hormone levels do not exclude adrenal insufficiency during immune checkpoint inhibitor therapy: Evidence from clinical, steroid, and structural analyses","volume":"16","author":"Ishibashi","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000030456","article-title":"New-onset type 1 diabetes mellitus as a delayed immune-related event after discontinuation of nivolumab: A case report","volume":"101","author":"Seo","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.764138","article-title":"Unravelling checkpoint inhibitor associated autoimmune diabetes: From bench to bedside","volume":"12","author":"Wu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0254-y","article-title":"The heterogeneous pathogenesis of type 1 diabetes mellitus","volume":"15","author":"Ilonen","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210012","article-title":"Anti-islet autoantibodies in type 1 diabetes","volume":"24","author":"Kawasaki","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-024-01263-6","article-title":"Distinct changes to pancreatic volume rather than pancreatic autoantibody positivity: Insights into immune checkpoint inhibitors induced diabetes mellitus","volume":"16","author":"Wei","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2019743117","article-title":"Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice","volume":"117","author":"Hu","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad685","article-title":"Checkpoint inhibitor-associated autoimmune diabetes mellitus is characterized by C-peptide loss and pancreatic atrophy","volume":"109","author":"Wu","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58081034","article-title":"Genetic polymorphism of PTPN22 in autoimmune diseases: A comprehensive review","volume":"58","author":"Tizaoui","year":"2022","journal-title":"Med (Kaunas)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02094-6","article-title":"Germline variants associated with toxicity to immune checkpoint blockade","volume":"28","author":"Groha","year":"2022","journal-title":"Nat Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006570","article-title":"Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors","volume":"11","author":"Caulfield","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ejca.2020.02.049","article-title":"Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency","volume":"130","author":"Yano","year":"2020","journal-title":"Eur J Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002493","article-title":"Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors","volume":"9","author":"Kobayashi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14082","article-title":"Comparative analysis of human leucocyte antigen between idiopathic and anti-PD-1 antibody induced isolated adrenocorticotropic hormone deficiency: A pilot study","volume":"91","author":"Inaba","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-022-01395-7","article-title":"Sex differences in immune-related adverse events with immune checkpoint inhibitors: Data mining of the FDA adverse event reporting system","volume":"44","author":"Chen","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-025-04447-w","article-title":"Sex differences in the onset and outcomes of immune checkpoint inhibitor-induced overt thyroid dysfunction: A retrospective study","volume":"90","author":"Bai","year":"2025","journal-title":"Endocrine"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1177\/2042018819896182","article-title":"Immunotherapy-induced endocrinopathies: Assessment, management and monitoring","volume":"10","author":"Nogueira","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14041057","article-title":"Immune checkpoint inhibitors as a threat to the hypothalamus-pituitary axis: A completed puzzle","volume":"14","author":"Barnabei","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1804","article-title":"Endocrine adverse events caused by different types and different doses of immune checkpoint inhibitors in the treatment of solid tumors: A meta-analysis and systematic review","volume":"61","author":"Yang","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: A pooled analysis of 23 clinical trials and 8,436 patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res Treat"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad670","article-title":"Risk and incidence of endocrine immune-related adverse effects under checkpoint inhibitor mono- or combination therapy in solid tumors: A meta-analysis of randomized controlled trials","volume":"109","author":"Vardarli","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-026-04635-2","article-title":"Endocrine toxicities in immune checkpoint inhibitors and tyrosine kinase inhibitors combined treatment: From clinical trials to real-life practice","volume":"91","author":"Chiloiro","year":"2026","journal-title":"Endocrine"},{"key":"B79","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13073-024-01285-9","article-title":"Gut microbiome for predicting immune checkpoint blockade-associated adverse events","volume":"16","author":"Hu","year":"2024","journal-title":"Genome Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032769","article-title":"Implication of the gut microbiome and microbial-derived metabolites in immune-related adverse events: Emergence of novel biomarkers for cancer immunotherapy","volume":"24","author":"Dora","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1099063","article-title":"Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.756872","article-title":"Intestinal microbiome associated with immune-related adverse events for patients treated with anti-PD-1 inhibitors, a real-world study","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-025-01026-w","article-title":"Roles of the gut microbiota in immune-related adverse events: Mechanisms and therapeutic intervention","volume":"22","author":"Gao","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33557","article-title":"Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting","volume":"149","author":"Takada","year":"2021","journal-title":"Int J Cancer"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.07.006","article-title":"Development and validation of a prediction model for thyroid dysfunction in patients during immunotherapy","volume":"30","author":"Wang","year":"2024","journal-title":"Endocr Pract"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1530\/erc-24-0101","article-title":"Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: A prospective study from a single tertiary center","volume":"31","author":"Barlas","year":"2024","journal-title":"Endocr Relat Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020375","article-title":"Predictive biomarkers for immune-related endocrinopathies following immune checkpoint inhibitors treatment","volume":"15","author":"Shalit","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14363","article-title":"Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors","volume":"111","author":"Kurimoto","year":"2020","journal-title":"Cancer Sci"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1733357","article-title":"A composite score of serum cytokines enables early identification of patients at high risk for irAEs under immune checkpoint inhibition","volume":"16","author":"Flatt","year":"2025","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1172\/jci192938","article-title":"Pancreatic volume and immune biomarkers predict checkpoint inhibitor-associated autoimmune diabetes in humans","volume":"136","author":"Wu","year":"2026","journal-title":"J Clin Invest"},{"key":"B91","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1038\/s41467-024-46195-x","article-title":"Single-cell profiling identifies IL1B(hi) macrophages associated with inflammation in PD-1 inhibitor-induced inflammatory arthritis","volume":"15","author":"Zhou","year":"2024","journal-title":"Nat Commun"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102734","article-title":"Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary group","volume":"126","author":"Zatelli","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1458488","article-title":"Biomarkers in the early stage of PD-1 inhibitor treatment have shown superior predictive capabilities for immune-related thyroid dysfunction","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012350","article-title":"Clonally expanded effector CD4(+) cytotoxic T lymphocytes are associated with severe neurological adverse events after immune checkpoint inhibitor therapy","volume":"13","author":"Giguelay","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B95","doi-asserted-by":"publisher","first-page":"18645","DOI":"10.1038\/s41598-025-02723-3","article-title":"Unraveling the mechanisms of irAEs in endometrial cancer immunotherapy: Insights from FAERS and scRNA-seq data","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci Rep"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1530\/ec-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: An updated review","volume":"9","author":"Stelmachowska-Bana\u015b","year":"2020","journal-title":"Endocr Connect"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000005440","article-title":"18 F-FDG PET\/CT for detection of immunotherapy-induced hypophysitis-a case-control study","volume":"49","author":"Fischer","year":"2024","journal-title":"Clin Nucl Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/cen.15240","article-title":"The utility of magnetic resonance imaging for hypophysitis secondary to immune checkpoint inhibitor use","volume":"102","author":"Qi","year":"2025","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B99","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1158\/1078-0432.Ccr-23-1469","article-title":"Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer","volume":"30","author":"Murray","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s43556-025-00291-6","article-title":"Liquid biopsy using plasma proteomics in predicting efficacy and tolerance of PD-1\/PD-L1 blockades in NSCLC: A prospective exploratory study","volume":"6","author":"Gao","year":"2025","journal-title":"Mol BioMed"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172806","article-title":"Comprehensive assessment of prognostic factors for immune-related adverse events in immune checkpoint inhibitor-treated melanoma","volume":"17","author":"K\u00f6tt","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2410557","article-title":"Exploring risk factors for endocrine-related immune-related adverse events: Insights from meta-analysis and Mendelian randomization","volume":"20","author":"Quan","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.08.003","article-title":"A risk stratification model for toxicities in phase 1 immunotherapy trials","volume":"175","author":"Hernando-Calvo","year":"2022","journal-title":"Eur J Cancer"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03816-0","article-title":"Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal","volume":"74","author":"Li","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/jebm.12558","article-title":"Scope, design, and reporting of prediction models for antineoplastic drugs-related adverse drug events: A systematic review of machine learning and traditional modeling","volume":"16","author":"Jiang","year":"2023","journal-title":"J Evid Based Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1935980\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:33:02Z","timestamp":1789561982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1935980\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":105,"alternative-id":["10.3389\/fendo.2026.1935980"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1935980","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1935980"}}